European Healthtech Grabs The Investor Headlines In H1 2022
Cautious Optimism For Sector And M&A Set To Stay Strong In 2022
After a runaway 2021 and a strong if bumpy Q1 2022, all health care product sectors underwent an investment dip in Q2, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.
You may also be interested in...
Architects of the major reform of secondary care reimbursement have asked for the input of hospitals just once, the DKG hospital federation complains. Meanwhile, many clinics are reportedly facing insolvency later this year.
BD and Boston Scientific exemplify the approach of “big medtech” as it knuckles down to meet global climate change responsibilities. But the industry will have to work together with health systems to achieve the larger race to zero goals – especially those of scope 3.
Much preparation work is underway among industry and the authorities as the UK seeks to nail down what kind of medtech regulatory system it wants for the future. Hosting an update session were the ABHI’s Phil Brown and Steve Lee.